A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis

BACKGROUND: Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Genome Med
Main Authors: Ross, Colin J., Towfic, Fadi, Shankar, Jyoti, Laifenfeld, Daphna, Thoma, Mathis, Davis, Matthew, Weiner, Brian, Kusko, Rebecca, Zeskind, Ben, Knappertz, Volker, Grossman, Iris, Hayden, Michael R.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5450152/
https://ncbi.nlm.nih.gov/pubmed/28569182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-017-0436-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados